Last reviewed · How we verify
palliative care group first-line scheme — Competitive Intelligence Brief
marketed
Palliative Care / Oncology Support
Small molecule
Live · refreshed every 30 min
Target snapshot
palliative care group first-line scheme (palliative care group first-line scheme) — Guang'anmen Hospital of China Academy of Chinese Medical Sciences. A palliative care regimen combining traditional Chinese medicine and supportive care approaches to manage symptoms and improve quality of life in advanced disease.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| palliative care group first-line scheme TARGET | palliative care group first-line scheme | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- palliative care group first-line scheme CI watch — RSS
- palliative care group first-line scheme CI watch — Atom
- palliative care group first-line scheme CI watch — JSON
- palliative care group first-line scheme alone — RSS
Cite this brief
Drug Landscape (2026). palliative care group first-line scheme — Competitive Intelligence Brief. https://druglandscape.com/ci/palliative-care-group-first-line-scheme. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab